secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0000950170-22-002285
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q4 2021 revenue $17.1M, cash $716.6M; FT596 data shows 69% ORR, FT516 gets RMAT
--------------------------------------------------------------------------------

- Q4 2021 revenue $17.1M from collaborations; R&D expenses $69.5M (incl. $9.4M stock comp).
- Cash position $716.6M at Dec 31, 2021; FY2022 GAAP loss from ops guided $335-365M; cash use $290-315M; year-end cash >$400M.
- FT596+R single-dose cohorts (≥90M cells, n=16): 69% ORR, 56% CR; no ICANS or GVHD.
- FDA granted RMAT designation for FT516 in r/r DLBCL; expansion cohorts enrolling at 900M cells/dose.
- Initial FT819 dose cohort cleared with no DLTs; Janssen collaboration triggered milestone for second CAR NK candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022002285/0000950170-22-002285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022002285/fate-20220228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer